September 17, 2024 Journal article Open Access

Demeke Daka1,2, Daniel Woldeyes1, Lemu Golassa3, Gezahegn Solomon Alemayehu4, Zerihun Zewde5, Girum Tamiru1, Tadesse Misganaw6, Fekadu Massebo1 and Biniam Wondale1

DCAT Export

<?xml version='1.0' encoding='utf-8'?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:adms="http://www.w3.org/ns/adms#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dct="http://purl.org/dc/terms/" xmlns:dctype="http://purl.org/dc/dcmitype/" xmlns:dcat="http://www.w3.org/ns/dcat#" xmlns:duv="http://www.w3.org/ns/duv#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:frapo="http://purl.org/cerif/frapo/" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:gsp="http://www.opengis.net/ont/geosparql#" xmlns:locn="http://www.w3.org/ns/locn#" xmlns:org="http://www.w3.org/ns/org#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:prov="http://www.w3.org/ns/prov#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:schema="http://schema.org/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:vcard="http://www.w3.org/2006/vcard/ns#" xmlns:wdrs="http://www.w3.org/2007/05/powder-s#">
  <rdf:Description rdf:about="https://doi.org/10.20372/nadre:17224">
    <dct:identifier rdf:datatype="http://www.w3.org/2001/XMLSchema#anyURI">https://doi.org/10.20372/nadre:17224</dct:identifier>
    <foaf:page rdf:resource="https://doi.org/10.20372/nadre:17224"/>
    <dct:creator>
      <rdf:Description>
        <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Agent"/>
        <foaf:name>Demeke Daka1,2, Daniel Woldeyes1, Lemu Golassa3, Gezahegn Solomon Alemayehu4, Zerihun Zewde5, Girum Tamiru1, Tadesse Misganaw6, Fekadu Massebo1 and Biniam Wondale1</foaf:name>
        <foaf:givenName>2, Daniel Woldeyes1, Lemu Golassa3, Gezahegn Solomon Alemayehu4, Zerihun Zewde5, Girum Tamiru1, Tadesse Misganaw6, Fekadu Massebo1 and Biniam Wondale1</foaf:givenName>
        <foaf:familyName>Demeke Daka1</foaf:familyName>
        <org:memberOf>
          <foaf:Organization>
            <foaf:name>1Department of Biology, Arba Minch University, Arba Minch, Ethiopia. 2Department of Biology, Madda Walabu University, Bale Robe, Ethiopia. 3Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia. 4Ethiopian Defence University College of Health Sciences, Bishoftu, Ethiopia. 5Arba Minch Public Health Laboratory, South Ethiopia Region Public Health Institute, Arba Minch, Ethiopia. 6Department of Medical Laboratory Science, Woldia University, Woldia, Ethiopia.</foaf:name>
          </foaf:Organization>
        </org:memberOf>
      </rdf:Description>
    </dct:creator>
    <dct:title>Therapeutic efficacy of artemether– lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Arba Minch Zuria District, Gamo Zone, Southwest Ethiopia</dct:title>
    <dct:publisher>
      <foaf:Agent>
        <foaf:name>Zenodo</foaf:name>
      </foaf:Agent>
    </dct:publisher>
    <dct:issued rdf:datatype="http://www.w3.org/2001/XMLSchema#gYear">2024</dct:issued>
    <dct:issued rdf:datatype="http://www.w3.org/2001/XMLSchema#date">2024-09-17</dct:issued>
    <owl:sameAs rdf:resource="https://nadre.ethernet.edu.et/record/17224"/>
    <adms:identifier>
      <adms:Identifier>
        <skos:notation rdf:datatype="http://www.w3.org/2001/XMLSchema#anyURI">https://nadre.ethernet.edu.et/record/17224</skos:notation>
        <adms:schemeAgency>url</adms:schemeAgency>
      </adms:Identifier>
    </adms:identifier>
    <dct:isVersionOf rdf:resource="https://doi.org/10.20372/nadre:17223"/>
    <dct:description>&lt;p&gt;Abstract&lt;br&gt; Background Artemether&amp;ndash;lumefantrine (AL) has been the primary anti-malarial drug used to treat uncomplicated&lt;br&gt; Plasmodium falciparum malaria in Ethiopia since 2004. However, there have been recent reports of AL resistance&lt;br&gt; mutations in different African countries, including Ethiopia. This is concerning and requires periodic monitoring&lt;br&gt; of anti-malarial drug resistance. Therefore, the current study aimed to evaluate the therapeutic efficacy of AL in treating uncomplicated P. falciparum malaria in the Arba Minch Zuria District, Gamo Zone, Southwest Ethiopia.&lt;br&gt; Methods A single-arm prospective study with a 28-day follow-up period was conducted from July to October 2022.&lt;br&gt; Capillary blood samples were collected for RDT and microscopic examination. The study enrolled monoinfected P.&lt;br&gt; falciparum patients aged &amp;ge; 18 years at Ganta Sira Health Post. Sociodemographic and clinical data were recorded,&lt;br&gt; and a dried blood spot (DBS) was prepared for each participant. Nested polymerase chain reaction (nPCR) genotyping&lt;br&gt; of the msp-1 and msp-2 genes was only performed for recurrent cases to distinguish between recurrence and reinfection. Data entry and analysis were performed using the WHO Excel spreadsheet and SPSS version 26.&lt;br&gt; Results A total of 89 patients were enrolled, and 67 adequately completed the 28-day follow-up period. AL showed&lt;br&gt; a 100% clearance rate for fever on day 2 and asexual parasites on day 3. Gametocytes were detected in 13.5% (12/89)&lt;br&gt; of the participants. The gametocyte clearance rate was 58.3% (7/12) until day 7 and 100% (12/12) until day 14. Five&lt;br&gt; participants developed recurrent malaria, three of whom experienced relapse and two of whom experienced reinfection. Based on the Kaplan&amp;ndash;Meier survival analysis, the PCR-uncorrected and PCR-corrected cumulative incidence&lt;br&gt; of success were 93.7% (95% CI 85.5&amp;ndash;97.3) and 96.2% (95% CI 85.5&amp;ndash;98.7), respectively.&lt;br&gt; Conclusion AL was efficacious in treating uncomplicated P. falciparum malaria in the study area. However, the detection of recurrent patients highlights the need for continuous efficacy studies in this area.&lt;br&gt; Keywords Cure rate, Parasite clearance, Recurrence, Malaria&lt;br&gt; &amp;nbsp;&lt;/p&gt;</dct:description>
    <dct:accessRights rdf:resource="http://publications.europa.eu/resource/authority/access-right/PUBLIC"/>
    <dct:accessRights>
      <dct:RightsStatement rdf:about="info:eu-repo/semantics/openAccess">
        <rdfs:label>Open Access</rdfs:label>
      </dct:RightsStatement>
    </dct:accessRights>
    <dct:rights>
      <dct:RightsStatement rdf:about="http://www.opendefinition.org/licenses/odc-by">
        <rdfs:label>Open Data Commons Attribution License</rdfs:label>
      </dct:RightsStatement>
    </dct:rights>
    <dcat:distribution>
      <dcat:Distribution>
        <dcat:accessURL rdf:resource="https://doi.org/10.20372/nadre:17224"/>
        <dcat:byteSize>1480123</dcat:byteSize>
        <dcat:downloadURL rdf:resource="https://nadre.ethernet.edu.et/record/17224/files/Therapeutic efficacy of artemether–.pdf"/>
        <dcat:mediaType>application/pdf</dcat:mediaType>
      </dcat:Distribution>
    </dcat:distribution>
  </rdf:Description>
</rdf:RDF>